Top

Published in:

Open Access 01-12-2012 | Poster presentation

AJAK inhibitor, tofacitinibreduces IL-6 and matrix metalloproteinase-3 productionin rheumatoid arthritis with suppressed cartilage destruction

Authors: Kunihiro Yamaoka, Satoshi Kubo, Koshiro Sonomoto, Keisuke Maeshima, Yoshiya Tanaka

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Excerpt

Tofacitinib, targeting Janus kiase (JAK) has gained attention as anorally available new disease modifying anti-rheumatic drug with high clinical efficacy against rheumatoid arthritis (RA). While the clinical trial has progressed and the wide usage of tofacitinib is conceivable in the near future, the precise mechanism of action in RA patients remains to be solved. …

Title: AJAK inhibitor, tofacitinibreduces IL-6 and matrix metalloproteinase-3 productionin rheumatoid arthritis with suppressed cartilage destruction
Authors: Kunihiro Yamaoka
Satoshi Kubo
Koshiro Sonomoto
Keisuke Maeshima
Yoshiya Tanaka
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar3678

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2012

The bacterial effector protein YopM reduces rheumatoid arthritis (RA) outcome by inhibiting inflammation and bone destruction

IL-17-producing ©™T cells are important for the development of arthritis in a rheumatoid arthritis model

T-regs/Th17 function defect in systemic autoimmunity as a result of "recent thymic emigrants" maturation defect

Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin

T cell receptor rearrangement excision circles (TREC) study as an approach to "in vivo" thymus gland function investigation

Active repression by Blimp1 play an important role in osteoclast differentiation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials